FDA: Vytorin "Unlikely" To Cause Cancer, But More Data Coming
This article was originally published in The Pink Sheet Daily
Executive Summary
SHARP and IMPROVE-IT trials will allow the agency to "further assess" the potential risk.
You may also be interested in...
Merck Still Plans Big Cost Savings This Year From Schering-Plough Deal
In his first public appearance since completing the acquisition last November of Schering-Plough, Merck chief executive Richard Clark told an investor conference that roughly half of the projected savings from the merger can be realized this year
Merck Still Plans Big Cost Savings This Year From Schering-Plough Deal
In his first public appearance since completing the acquisition last November of Schering-Plough, Merck chief executive Richard Clark told an investor conference that roughly half of the projected savings from the merger can be realized this year
IMPROVEd Timing On Vytorin Outcomes Data?
Full results from the massive study will be delayed a year, but an earlier interim analysis could help resolve questions about the safety and efficacy of Merck's cholesterol drug.